SBTX
Income statement / Annual
Last year (2022), Silverback Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Silverback Therapeutics, Inc.'s net income was -$33.85 M.
See Silverback Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$18.38 M
|
$61.50 M
|
$24.58 M
|
$21.51 M
|
$14.80 M
|
| General & Administrative Expenses |
$18.46 M
|
$28.08 M
|
$8.34 M
|
$2.56 M
|
$3.52 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$18.46 M
|
$28.08 M
|
$8.34 M
|
$2.56 M
|
$3.52 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$36.83 M
|
$89.58 M
|
$32.92 M
|
$24.07 M
|
$18.32 M
|
| Cost And Expenses |
$36.83 M
|
$89.58 M
|
$32.92 M
|
$24.07 M
|
$18.32 M
|
| Interest Income |
$0.00
|
$0.00
|
-$29,000.00
|
$100,000.00
|
$43,000.00
|
| Interest Expense |
-$834,000.00
|
$106,000.00
|
-$29,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$319,000.00
|
$783,000.00
|
$637,000.00
|
$544,000.00
|
$480,000.00
|
| EBITDA |
-$35.52 M |
-$88.59 M |
-$32.31 M |
-$23.42 M |
-$17.10 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$834,000.00
|
$106,000.00
|
-$29,000.00
|
$100,000.00
|
$741,000.00
|
| Income Before Tax |
-$34.68 M
|
-$89.48 M
|
-$32.95 M
|
-$23.97 M
|
-$17.58 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$834,000.00
|
$106,000.00
|
-$29,000.00
|
$100,000.00
|
$741,000.00
|
| Net Income |
-$33.85 M
|
-$89.58 M
|
-$32.95 M
|
-$23.97 M
|
-$17.58 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
| EPS |
-0.85 |
-30.81 |
-11.33 |
-4.9 |
-3.59 |
| EPS Diluted |
-0.85 |
-30.81 |
-11.33 |
-4.9 |
-3.59 |
| Weighted Average Shares Out |
$39.96 M
|
$2.91 M
|
$2.91 M
|
$4.89 M
|
$4.89 M
|
| Weighted Average Shares Out Diluted |
$39.96 M
|
$2.91 M
|
$2.91 M
|
$4.89 M
|
$4.89 M
|
| Link |
|
|
|
|
|
